Finepoint Capital LP Has $13.68 Million Position in Arvinas, Inc. (NASDAQ:ARVN)

Finepoint Capital LP raised its stake in shares of Arvinas, Inc. (NASDAQ:ARVN) by 24.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 713,778 shares of the company’s stock after purchasing an additional 139,400 shares during the period. Arvinas accounts for approximately 0.8% of Finepoint Capital LP’s investment portfolio, making the stock its 13th biggest position. Finepoint Capital LP owned approximately 1.04% of Arvinas worth $13,683,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Arvinas by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock worth $135,389,000 after buying an additional 56,561 shares during the period. FMR LLC boosted its holdings in Arvinas by 7.6% during the 3rd quarter. FMR LLC now owns 2,883,604 shares of the company’s stock worth $71,023,000 after acquiring an additional 204,317 shares during the last quarter. JPMorgan Chase & Co. grew its position in Arvinas by 18.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after purchasing an additional 367,343 shares in the last quarter. Norges Bank bought a new position in Arvinas in the 4th quarter valued at $23,845,000. Finally, Charles Schwab Investment Management Inc. grew its position in Arvinas by 1.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 536,112 shares of the company’s stock valued at $10,277,000 after buying an additional 5,443 shares during the period. Institutional investors own 95.19% of the company’s stock.

Insider Buying and Selling

In related news, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ian Taylor sold 9,020 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,230 shares of company stock worth $769,402 in the last three months. 5.23% of the stock is owned by corporate insiders.

Arvinas Price Performance

ARVN stock opened at $6.56 on Friday. The firm has a 50-day moving average of $14.15 and a 200 day moving average of $20.04. The company has a market cap of $451.14 million, a P/E ratio of -2.37 and a beta of 2.30. Arvinas, Inc. has a 1 year low of $6.24 and a 1 year high of $39.34.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the firm earned ($2.53) EPS. On average, equities research analysts expect that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ARVN has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Wells Fargo & Company set a $26.00 price objective on Arvinas and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $81.00 price target on shares of Arvinas in a research report on Tuesday, March 11th. Guggenheim decreased their price objective on shares of Arvinas from $57.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Finally, Bank of America dropped their target price on shares of Arvinas from $54.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, March 12th. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $35.50.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.